Answer
Linagliptin inhibits DPP‑4, prolonging active GLP‑1 and GIP incretin levels, which increases insulin secretion and lowers glucagon secretion in a glucose-dependent manner, reducing liver glucose output and improving blood glucose control.
Sources for this answer
- Trajenta 5 mg film-coated tabletsBoehringer Ingelheim Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 18Document updated
Sources checked